Emerging Infectious Diseases

Our deep immunological and infectious disease expertise, coupled with our flexible funding structure, has allowed us to respond quickly to emerging infectious diseases throughout the years.

Ragon scientists have been able to respond swiftly to new diseases from COVID-19 to Zika, thanks in part to our incredible, donor-supported flexible funding model.

We work towards understanding, preventing, and treating these diseases while identifying and studying viruses which could potentially turn pathogenic in the future.

Our labs have helped support vaccine development for COVID-19 and Zika, work to understand high-risk viral classes such as flaviviruses, and analyze the immune response to novel pathogenic viruses.

Labs Working in this Area

On Site Labs

Alter

Systems Serology

Galit Alter, PhD

LAB INFO

Balazs

Engineering Immunity Against Infectious Disease

Alejandro B. Balazs, PhD

LAB INFO

Batista

B cells, antibodies, preclinical vaccinology

Facundo Batista, PhD

LAB INFO

Lichterfeld

Clinical trials, single cell assays, HIV cure

Mathias D. Lichterfeld, MD, PhD

LAB INFO

Schmidt

Protein Engineering, Therapeutic Development, Viral Evolution

Aaron Schmidt, PhD

LAB INFO

Shalek

Single-Cell Genomics, Systems Immunology

Alex K. Shalek, PhD

LAB INFO

Walker

HIV, virus-specific T cells, elite controllers

Bruce D. Walker, MD

LAB INFO